283 related articles for article (PubMed ID: 26026426)
1. Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model.
Lyons MA; Lenaerts AJ
J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):375-89. PubMed ID: 26026426
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.
Jayaram R; Gaonkar S; Kaur P; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharat S; Shandil RK; Kantharaj E; Balasubramanian V
Antimicrob Agents Chemother; 2003 Jul; 47(7):2118-24. PubMed ID: 12821456
[TBL] [Abstract][Full Text] [Related]
3. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
Alfarisi O; Alghamdi WA; Al-Shaer MH; Dooley KE; Peloquin CA
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1027-1036. PubMed ID: 28803492
[TBL] [Abstract][Full Text] [Related]
4. A physiologically based pharmacokinetic model of rifampin in mice.
Lyons MA; Reisfeld B; Yang RS; Lenaerts AJ
Antimicrob Agents Chemother; 2013 Apr; 57(4):1763-71. PubMed ID: 23357766
[TBL] [Abstract][Full Text] [Related]
5. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.
Aarnoutse RE; Kibiki GS; Reither K; Semvua HH; Haraka F; Mtabho CM; Mpagama SG; van den Boogaard J; Sumari-de Boer IM; Magis-Escurra C; Wattenberg M; Logger JGM; Te Brake LHM; Hoelscher M; Gillespie SH; Colbers A; Phillips PPJ; Plemper van Balen G; Boeree MJ;
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827417
[TBL] [Abstract][Full Text] [Related]
7. Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model.
de Steenwinkel JE; Aarnoutse RE; de Knegt GJ; ten Kate MT; Teulen M; Verbrugh HA; Boeree MJ; van Soolingen D; Bakker-Woudenberg IA
Am J Respir Crit Care Med; 2013 May; 187(10):1127-34. PubMed ID: 23525933
[TBL] [Abstract][Full Text] [Related]
8. A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.
Pienaar E; Cilfone NA; Lin PL; Dartois V; Mattila JT; Butler JR; Flynn JL; Kirschner DE; Linderman JJ
J Theor Biol; 2015 Feb; 367():166-179. PubMed ID: 25497475
[TBL] [Abstract][Full Text] [Related]
9. Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin-Treated Pulmonary Tuberculosis.
Svensson RJ; Simonsson U
CPT Pharmacometrics Syst Pharmacol; 2016 May; 5(5):264-73. PubMed ID: 27299939
[TBL] [Abstract][Full Text] [Related]
10. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA
Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182
[TBL] [Abstract][Full Text] [Related]
11. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.
Gumbo T; Louie A; Deziel MR; Liu W; Parsons LM; Salfinger M; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3781-8. PubMed ID: 17724157
[TBL] [Abstract][Full Text] [Related]
12. Forecasting Clinical Dose-Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin.
Wicha SG; Clewe O; Svensson RJ; Gillespie SH; Hu Y; Coates ARM; Simonsson USH
Clin Pharmacol Ther; 2018 Dec; 104(6):1208-1218. PubMed ID: 29700814
[TBL] [Abstract][Full Text] [Related]
13. The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model.
Chen C; Ortega F; Rullas J; Alameda L; Angulo-Barturen I; Ferrer S; Simonsson US
J Pharmacokinet Pharmacodyn; 2017 Apr; 44(2):133-141. PubMed ID: 28205025
[TBL] [Abstract][Full Text] [Related]
14. Computational pharmacology of rifampin in mice: an application to dose optimization with conflicting objectives in tuberculosis treatment.
Lyons MA
J Pharmacokinet Pharmacodyn; 2014 Dec; 41(6):613-23. PubMed ID: 25173151
[TBL] [Abstract][Full Text] [Related]
15. Selective malabsorption and the origin of mono-rifampin-resistant Mycobacterium tuberculosis.
Perlman DC; Salomon N
Am J Respir Crit Care Med; 1996 Oct; 154(4 Pt 1):1213. PubMed ID: 8887622
[No Abstract] [Full Text] [Related]
16. Pharmacokinetics and dose response of anti-TB drugs in rat infection model of tuberculosis.
Kumar N; Vishwas KG; Kumar M; Reddy J; Parab M; Manikanth CL; Pavithra BS; Shandil RK
Tuberculosis (Edinb); 2014 May; 94(3):282-6. PubMed ID: 24629633
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
Ruslami R; Nijland HM; Alisjahbana B; Parwati I; van Crevel R; Aarnoutse RE
Antimicrob Agents Chemother; 2007 Jul; 51(7):2546-51. PubMed ID: 17452486
[TBL] [Abstract][Full Text] [Related]
18. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
Li J; Munsiff SS; Driver CR; Sackoff J
Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767
[TBL] [Abstract][Full Text] [Related]
19. Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin.
Goutelle S; Bourguignon L; Jelliffe RW; Conte JE; Maire P
J Theor Biol; 2011 Aug; 282(1):80-92. PubMed ID: 21605569
[TBL] [Abstract][Full Text] [Related]
20. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
